Table 3.
Breast treatment* characteristics
| Treatment characteristics | Overall N = 508 |
Tape measurement N = 245 |
BIS N = 263 |
p (value) |
|---|---|---|---|---|
| Type of surgery, n (%) | ||||
| Breast conservation | 401 (78.9) | 189 (77.1) | 212 (80.6) | 0.338 |
| Mastectomy | 107 (21.1) | 56 (22.9) | 51 (19.4) | |
| Reconstruction, n (%)a | 89 (17.6) | 46 (18.8) | 43 (16.4) | 0.485 |
| Node dissection, n (%) | 493 (97.0) | 239 (97.6) | 254 (96.6) | 0.517 |
| Dissection typeb | 0.392 | |||
| ALND only | 46 (9.3) | 22 (9.2) | 24 (9.4) | |
| SLNB only | 377 (76.6) | 176 (73.9) | 201 (79.1) | |
| ALND and SLNB | 59 (12.0) | 34 (14.3) | 25 (9.8) | |
| Otherc | 10 (2.0) | 6 (2.5) | 4 (1.6) | |
| SLNB only | 0.291 | |||
| <6 nodes | 362 (96.0) | 167 (94.9) | 195 (97.0) | |
| ≥6 nodes | 15 (4.0) | 9 (5.1) | 6 (3.0) | |
| Total number of nodes dissected (Median [IQR], N) | 3.0 [2–5], 493 | 3.0 [2–5], 239 | 3.0 [2–4], 254 | 0.090 |
| Total number of positive nodes (Median [IQR], N) | 0.0 [0–1], 493 | 0.0 [0–1], 239 | 0 [0–0], 254 | 0.269 |
| N = 507 | N = 244 | N = 263 | p value | |
|---|---|---|---|---|
| Chemotherapy, n (%) | 213 (42.0) | 106 (43.4) | 107 (40.7) | 0.530 |
| Neoadjuvant | 24 (11.3) | 11 (10.4) | 13 (12.1) | 0.893 |
| Adjuvant | 164 (77.0) | 83 (78.3) | 81 (75.8) | |
| Both | 25 (11.7) | 12 (11.3) | 13 (12.1) | |
| Chemotherapy type (if received) | 0.836 | |||
| Any taxane | 192 (90.1) | 96 (90.6) | 96 (89.7) | |
| Other (non-taxane) | 21 (9.9) | 10 (9.4) | 11 (10.3) | |
| Radiation therapy, n (%) | 430 (84.6) | 203 (82.9) | 227 (86.3) | 0.280 |
| Boostd | 316 (75.4) | 151 (76.3) | 165 (74.7) | 0.704 |
| Radiation location | ||||
| Breast/chest wall | 425 (99.8) | 200 (99.5) | 225 (100.0) | 0.289 |
| Regional nodes | 95 (22.3) | 45 (22.4) | 50 (22.2) | 0.967 |
| N = 507 | N = 244 | N = 263 | p value | |
|---|---|---|---|---|
| Endocrine therapy, n (%) | 397 (78.3) | 181 (74.2) | 216 (82.1) | 0.030 |
| N = 503 | N = 245 | N = 258 | p value | |
|---|---|---|---|---|
| Complete treatment, n (%) | 0.798 | |||
| Surgery | 43 (8.5) | 24 (9.8) | 19 (7.4) | |
| Surgery + radiotherapy | 254 (50.5) | 117 (47.8) | 137 (53.1) | |
| Surgery + chemotherapy (taxane) | 34 (6.8) | 19 (7.8) | 15 (5.8) | |
| Surgery + chemotherapy (not taxane) | 2 (0.4) | 1 (0.4) | 1 (0.4) | |
| Surgery + radiotherapy + chemotherapy (taxane) | 153 (30.4) | 76 (31.0) | 77 (29.8) | |
| Surgery + radiotherapy + chemotherapy (not taxane) | 17 (3.4) | 8 (3.3) | 9 (3.5) | |
Bold value indicates statistical significance (p < 0.05)
All participants underwent surgery
BIS bioimpedance spectroscopy, ALND axillary lymph node dissection, SLNB sentinel lymph node biopsy, IQR interquartile range
aN = 507; BIS N = 262
bOne type of axillary surgery was unknown, N = 492
cIncluding interpectoral, intramammary, non-sentinel, and unknown type
dN = 419; tape measurement N = 198, BIS N = 221